AMTX vs INCY · rev $117.3M vs P/E 14, rev $5.14B
Aemetis Inc (AMTX) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
Aemetis Inc (AMTX) is a specialty chemicals company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported AMTX revenue for 2026-06-30 was $117.3M. Net income was -$31.1M. AMTX currently screens at market cap $158.3M.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
AMTX currently screens at market cap $158.3M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the AMTX and INCY stock pages for the full models.
Not investment advice.